BIOMARKERS IN DRUG DEVELOPMENT

A Handbook of Practice, Application, and Strategy

Edited by

MICHAEL R. BLEAVINS, Ph.D., DABT
Michigan Technology and Research Institute
Ann Arbor, Michigan

CLAUDIO CARINI, M.D., Ph.D., FRCPath
Fresenius Biotech of North America
Waltham, Massachusetts

MALLÉ JURIMA-ROMET, Ph.D.
MDS Pharma Services
Montreal, Quebec, Canada

RAMIN RAHBARI, M.S.
Innovative Scientific Management
New York, New York

WILEY
A JOHN WILEY & SONS, INC., PUBLICATION
CONTENTS

CONTRIBUTORS ix
PREFACE xv

PART I BIOMARKERS AND THEIR ROLE IN DRUG DEVELOPMENT 1

1 Biomarkers Are Not New 3
Ian Dews

2 Biomarkers: Facing the Challenges at the Crossroads of Research and Health Care 15
Gregory J. Downing

3 Enabling Go/No Go Decisions 31
J. Fred Pritchard and Mallé Jurima-Romet

PART II IDENTIFYING NEW BIOMARKERS: TECHNOLOGY APPROACHES 41

4 Imaging as a Localized Biomarker: Opportunities and Challenges 43
Jonathan B. Moody, Philip S. Murphy, and Edward P. Ficaro

5 Protein Biomarker Discovery Using Mass Spectrometry-Based Proteomics 101
Joanna M. Hunter and Daniel Chelsky

6 Quantitative Multiplexed Patterning of Immune-Related Biomarkers 121
Dominic Eisinger, Ralph McDade, and Thomas Joos
7 Gene Expression Profiles as Preclinical and Clinical Cancer Biomarkers of Prognosis, Drug Response, and Drug Toxicity 135
Jason A. Sprowl and Amadeo M. Parissenti

8 Use of High-Throughput Proteomic Arrays for the Discovery of Disease-Associated Molecules 155
Douglas M. Molina, W. John W. Morrow, and Xiaowu Liang

PART III CHARACTERIZATION AND VALIDATION 177

9 Characterization and Validation Biomarkers in Drug Development: Regulatory Perspective 179
Federico Goodsaid

10 Fit-for-Purpose Method Validation and Assays for Biomarker Characterization to Support Drug Development 187
Jean W. Lee, Yuling Wu, and Jin Wang

11 Molecular Biomarkers from a Diagnostic Perspective 215
Klaus Lindpaintner

12 Strategies for the Co-Development of Drugs and Diagnostics: FDA Perspective on Diagnostics Regulation 231
Francis Kalush and Steven Gutman

13 Importance of Statistics in the Qualification and Application of Biomarkers 247
Mary Zacour

PART IV BIOMARKERS IN DISCOVERY AND PRECLINICAL SAFETY 287

14 Qualification of Safety Biomarkers for Application to Early Drug Development 289
William B. Mattes and Frank D. Sistare

15 Development of Serum Calcium and Phosphorus as Clinical Biomarkers for Drug-Induced Systemic Mineralization: Case Study with a MEK Inhibitor 301
Alan P. Brown

16 Biomarkers for the Immunogenicity of Therapeutic Proteins and Its Clinical Consequences 323
Claire Cornips and Huub Schellekens

17 New Markers of Kidney Injury 335
Sven A. Beushausen
PART V  TRANSLATING FROM PRECLINICAL RESULTS TO CLINICAL AND BACK 359

18 Translational Medicine—A Paradigm Shift in Modern Drug Discovery and Development: The Role of Biomarkers 361

19 Clinical Validation and Biomarker Translation 375
David Lin, Andreas Scherer, Raymond Ng, Robert Balshaw, Shawna Flynn, Paul Keown, Robert McMaster, and Bruce McManus

20 Predicting and Assessing an Inflammatory Disease and Its Complications: Example from Rheumatoid Arthritis 399
Christina Trollmo and Lars Klareskog

21 Pharmacokinetic and Pharmacodynamic Biomarker Correlations 413
J.F. Marier and Keith Gallicano

22 Validating In Vitro Toxicity Biomarkers Against Clinical Endpoints 433
Calvert Louden and Ruth A. Roberts

PART VI  BIOMARKERS IN CLINICAL TRIALS 443

23 Opportunities and Pitfalls Associated with Early Utilization of Biomarkers: Case Study in Anticoagulant Development 445
Kay A. Criswell

24 Integrating Molecular Testing Into Clinical Applications 463
Anthony A. Killeen

25 Biomarkers for Lysosomal Storage Disorders 475
Ari Zimran, Candida Fratazzi, and Deborah Elstein

26 Value Chain in the Development of Biomarkers for Disease Targets 485
Charles W. Richard, III, Arthur O. Tzianabos, and Whaijen Soo

PART VII  LESSONS LEARNED: PRACTICAL ASPECTS OF BIOMARKER IMPLEMENTATION 493

27 Biomarkers in Pharmaceutical Development: The Essential Role of Project Management and Teamwork 495
Lena King, Mallé Jurima-Romet, and Nita Ichhpurani
<table>
<thead>
<tr>
<th>Chapter</th>
<th>Title</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>28</td>
<td>Integrating Academic Laboratories Into Pharmaceutical Development</td>
<td>515</td>
</tr>
<tr>
<td></td>
<td><em>Peter A. Ward and Kent J. Johnson</em></td>
<td></td>
</tr>
<tr>
<td>29</td>
<td>Funding Biomarker Research and Development Through the Small Business Innovative Research Program</td>
<td>527</td>
</tr>
<tr>
<td></td>
<td><em>James Varani</em></td>
<td></td>
</tr>
<tr>
<td>30</td>
<td>Novel and Traditional Nonclinical Biomarker Utilization in the Estimation of Pharmaceutical Therapeutic Indices</td>
<td>541</td>
</tr>
<tr>
<td></td>
<td><em>Bruce D. Car, Brian Gemzik, and William R. Foster</em></td>
<td></td>
</tr>
<tr>
<td>31</td>
<td>Anti-Unicorn Principle: Appropriate Biomarkers Don’t Need to Be Rare or Hard to Find</td>
<td>551</td>
</tr>
<tr>
<td></td>
<td><em>Michael R. Bleavins and Ramin Rahbari</em></td>
<td></td>
</tr>
<tr>
<td>32</td>
<td>Biomarker Patent Strategies: Opportunities and Risks</td>
<td>565</td>
</tr>
<tr>
<td></td>
<td><em>Cynthia M. Bott and Eric J. Baude</em></td>
<td></td>
</tr>
</tbody>
</table>

**PART VIII  WHERE ARE WE HEADING AND WHAT DO WE REALLY NEED?**

<table>
<thead>
<tr>
<th>Chapter</th>
<th>Title</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>33</td>
<td>IT Supporting Biomarker-Enabled Drug Development</td>
<td>577</td>
</tr>
<tr>
<td></td>
<td><em>Michael Hehenberger</em></td>
<td></td>
</tr>
<tr>
<td>34</td>
<td>Redefining Disease and Pharmaceutical Targets Through Molecular Definitions and Personalized Medicine</td>
<td>593</td>
</tr>
<tr>
<td></td>
<td><em>Craig P. Webb, John F. Thompson, and Bruce H. Littman</em></td>
<td></td>
</tr>
<tr>
<td>35</td>
<td>Ethics of Biomarkers: The Borders of Investigative Research, Informed Consent, and Patient Protection</td>
<td>625</td>
</tr>
<tr>
<td></td>
<td><em>Heather Walmsley, Michael Burgess, Jacquelyn Brinkman, Richard Hegele, Janet Wilson-McManus, and Bruce McManus</em></td>
<td></td>
</tr>
<tr>
<td>36</td>
<td>Pathodynamics: Improving Biomarker Selection by Getting More Information from Changes Over Time</td>
<td>643</td>
</tr>
<tr>
<td></td>
<td><em>Donald C. Trost</em></td>
<td></td>
</tr>
<tr>
<td>37</td>
<td>Optimizing the Use of Biomarkers for Drug Development: A Clinician’s Perspective</td>
<td>693</td>
</tr>
<tr>
<td></td>
<td><em>Alberto Gimona</em></td>
<td></td>
</tr>
<tr>
<td>38</td>
<td>Nanotechnology-Based Biomarker Detection</td>
<td>709</td>
</tr>
<tr>
<td></td>
<td><em>Joshua Reineke</em></td>
<td></td>
</tr>
</tbody>
</table>

**INDEX**

731